Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer
Authors:
- 1 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 50 (3) , 313-316
Abstract
Objectives: The aim of this study was to clarify the effectiveness of combination chemotherapy targeting gemcitabine (GEM)–induced nuclear factor kappa B as adjuvant therapy for pancreatic cancer. Methods: Patients who were planned after curative surgery (residual tumor classification R0 or R1) for pancreatic cancer to receive six cycles of adjuvant chemotherapy of regional arterial infusion of nafamostat mesilate with GEM between June 2011 and April 2017 were enrolled in this single-center, institutional review board–approved phase II trial (UMIN000006163). The Kaplan-Meier method was used to estimate disease-free survival and overall survival. Results: In 32 patients [male/female: 18/14; age: median, 65.5 years (range, 48–77 years); pathological stage (Union for International Cancer Control 8th): IA/IB/IIA/IIB/III, 2/2/9/18/1, respectively] who met the eligibility criteria, the median overall survival and disease-free survival were 36.4 months (95% confidence interval, 31.7–48.3) and 16.4 months (95% confidence interval, 14.3–22.0), respectively. Grade 4 treatment-related hematological toxicities were seen in 5 patients (15.6%) (all neutropenia). One patient developed grade 3 nonhematological toxicities (rash). Conclusions: Adjuvant chemotherapy with regional arterial infusion of nafamostat mesilate and GEM is safe and has potential as an option in adjuvant setting after curative surgery for pancreatic cancer.Keywords
This publication has 18 references indexed in Scilit:
- Phase II Study of Gemcitabine in Combination With Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic CancerAmerican Journal of Clinical Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- The Results of Severe Acute Pancreatitis Treatment With Continuous Regional Arterial Infusion of Protease Inhibitor and AntibioticPancreas, 2010
- Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma: Who Really Benefits?Journal of the American College of Surgeons, 2009
- A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancerAnnals of Oncology, 2008
- Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitisJournal of Gastroenterology, 2007
- Expression of Concern: Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell deathCancer, 2007
- Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1α in Induction of Constitutive NF-κB Activation in Pancreatic Cancer CellsJournal of Biological Chemistry, 2004
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting ductBritish Journal of Pharmacology, 1994